Back to Search
DAVID ANDES, MD
MD
Infectious Disease Physician
NPI: 1154398857IndividualAccepts Medicare
Specialties, Licenses & Credentials
Infectious Disease PhysicianPrimary
Internal Medicine — Infectious Disease
Code: 207RI0200X
35020(WI)
CMS Specialties
PrimaryINFECTIOUS DISEASE
Education
OTHER
Class of 1992
Research & Publications (20)
In vivo pharmacodynamic characterization of a novel plectasin antibiotic, NZ2114, in a murine infection model.
PMID 19414576·Antimicrob Agents Chemother·2009
7-preclinical
Antifungal therapeutic drug monitoring: established and emerging indications.
PMID 18955533·Antimicrob Agents Chemother·2009
6-review
In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model.
PMID 18070979·Antimicrob Agents Chemother·2008
7-preclinical
In vivo pharmacodynamic target investigation for micafungin against Candida albicans and C. glabrata in a neutropenic murine candidiasis model.
PMID 18625768·Antimicrob Agents Chemother·2008
7-preclinical
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
PMID 17307987·Antimicrob Agents Chemother·2007
7-preclinical
Pharmacodynamics of a new streptogramin, XRP 2868, in murine thigh and lung infection models.
PMID 16377693·Antimicrob Agents Chemother·2006
7-preclinical
Impact of antimicrobial dosing regimen on evolution of drug resistance in vivo: fluconazole and Candida albicans.
PMID 16801415·Antimicrob Agents Chemother·2006
7-preclinical
Pharmacokinetics and pharmacodynamics of antifungals.
PMID 16984875·Infect Dis Clin North Am·2006
6-review
In vivo fluconazole pharmacodynamics and resistance development in a previously susceptible Candida albicans population examined by microbiologic and transcriptional profiling.
PMID 16801416·Antimicrob Agents Chemother·2006
7-preclinical
Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic-pharmacodynamic target.
PMID 16569855·Antimicrob Agents Chemother·2006
7-preclinical
Pharmacokinetic-pharmacodynamic comparison of amphotericin B (AMB) and two lipid-associated AMB preparations, liposomal AMB and AMB lipid complex, in murine candidiasis models.
PMID 16436726·Antimicrob Agents Chemother·2006
4-observational
Treatment of infections with ESBL-producing organisms: pharmacokinetic and pharmacodynamic considerations.
PMID 16209701·Clin Microbiol Infect·2005
4-observational
A simple approach for estimating gene expression in Candida albicans directly from a systemic infection site.
PMID 16088840·J Infect Dis·2005
4-observational
Use of an animal model of disseminated candidiasis in the evaluation of antifungal therapy.
PMID 15888938·Methods Mol Med·2005
7-preclinical
Fungal pathogenesis: bridging the gap between the bedside and the bench.
PMID 15770460·Mycopathologia·2005
8-other
Antifungal pharmacokinetics and pharmacodynamics: understanding the implications for antifungal drug resistance.
PMID 15296860·Drug Resist Updat·2004
6-review
Clinical utility of antifungal pharmacokinetics and pharmacodynamics.
PMID 15640707·Curr Opin Infect Dis·2004
6-review
Development and characterization of an in vivo central venous catheter Candida albicans biofilm model.
PMID 15385506·Infect Immun·2004
7-preclinical
Application of pharmacokinetics and pharmacodynamics to antimicrobial therapy of respiratory tract infections.
PMID 15177850·Clin Lab Med·2004
6-review
Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis.
PMID 14693531·Antimicrob Agents Chemother·2004
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 600 HIGHLAND AVE
MADISON, WI 53792 - Phone
- (608) 263-0943
Quick Facts
- NPI
- 1154398857
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 34
- Publications
- 20
Are you this provider?
Claim Your Profile